Igc Pharma Inc (IGC) Stock Price, Quote & News

Company Profile

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63, IGC-M3, and LMP to treat Alzheimer's disease; IGC-1C for the treatment of metabolic disorders and Alzheimer's disease; and IGC-1A to treat metabolic disorders. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 983 0998

Website: igcpharma.com

Address:

10224 Falls Road, Potomac, United States

CarlSpagler Dec. 26 at 9:05 PM

$IGC where do these analyst price targets come from? lol

1 · Reply

Amraa2 Dec. 26 at 8:08 PM

$IGC why so fking hard to get to .5

0 · Reply

theflynews Dec. 26 at 6:48 PM

Trump Weekly: President strikes deal with drugmakers, delays some tariffs - $IGC - https://thefly.com/permalinks/entry.php/IGCid4262021?176

0 · Reply

UCIdidmyDD Dec. 25 at 5:26 PM

$MSOS $MSOX $VFF $IGC $CVSI Merry Christmas tis the season to recall, we are not measured by what we have but by what we give back. Adopt a pet. be a big brother. be a light. I know its not the message of social media, but we all can make a difference, one choice at a time.

2 · Reply

dwiz5 Dec. 24 at 1:34 AM

$IGC 35,183 shares great dip buying G/L

0 · Reply

Ottway Dec. 23 at 3:04 PM

$IGC dilution king $CGC $TLRY these companies dont make money they scam us by rs and dilution… insanity how retail got dumped on

1 · Reply

Ottway Dec. 22 at 11:45 PM

$CGC dilution killed the rally baby $IGC amazing how these companies operate amazing this is legal…

0 · Reply

Jimbob3016 Dec. 22 at 12:27 PM

TLX Phase 3 approval $FLGC #1 on Stocktwits $IGC squeeze

0 · Reply

PineappleInvesting Dec. 22 at 7:09 AM

GREEN CHRISTMAS: POT STOCKS BLAZING $IGC $CGC $FLGC Trump rescheduling talk + patents + restructuring = pot stocks ready to EXPLODE ** $IGC （$0.3033， +1.10%）** Volume: 3.11M vs 841K = **3.7x SURGE** Float: $28.20M (MICRO) Patent secured for cannabinoid treatment • Squeeze: 64% to 52-wk high ** • JUICE: 9/10** - MAXIMUM SQUEEZE SETUP ** • $CGC ($1.55, +4.73%)** • Volume: 64.50M vs 52.21M = 1.24x ID Float: $541.96M "Down 99%, time to buy?" • Squeeze: 98% to 52-wk high (potential double) ** JUICE: 7/10** - Momentum play ** • $FLGC ($7.84)** Volume: 95.44K vs 60.49K = 1.58x Ip Float: $5.52M (ULTRA MICRO!) Rebranding to ZeroStack + restructuring • Squeeze: **500% to 52-wk high ($47) = 6x!** ** JUICE: 6/10** - Lottery ticket play **SANTA RALLY ODDS:** • IGC (90%) - Patent + volume + micro = EXPLOSIVE CGC (70%) - Brand name + Trump = steady • FLGC (50%) - 6x potential but high risk Loading heavy on $IGC for maximum juice #cannabis #potstocks #pennystock

0 · Reply

Clkrrb Dec. 19 at 6:55 PM

$IGC IGC’s Santa Claus rally is giving us a lump of coal.

0 · Reply

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

Dec 15, 2025, 9:00 AM EST - 12 days ago

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

Dec 10, 2025, 9:00 AM EST - 17 days ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock.

Dec 9, 2025, 9:00 AM EST - 18 days ago

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Dec 2, 2025, 9:00 AM EST - 25 days ago

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

Nov 25, 2025, 9:00 AM EST - 4 weeks ago

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

Nov 17, 2025, 8:30 AM EST - 5 weeks ago

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Nov 13, 2025, 9:00 AM EST - 6 weeks ago

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

Nov 10, 2025, 9:00 AM EST - 6 weeks ago

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

Nov 3, 2025, 8:52 AM EST - 7 weeks ago

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

Oct 22, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

Oct 14, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

Oct 10, 2025, 7:50 PM EDT - 2 months ago

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

Oct 7, 2025, 9:00 AM EDT - 2 months ago

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

Sep 29, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial

Sep 24, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Announces Preclinical Data Demonstrating TGR-63's Dual Action on Alzheimer's Pathology

Sep 22, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

Sep 9, 2025, 9:00 AM EDT - 3 months ago

IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection

Sep 2, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada

Aug 28, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome

Aug 27, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock.

Aug 25, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City

Aug 19, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial

Aug 12, 2025, 9:00 AM EDT - 4 months ago

IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1

Aug 5, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression

Jul 23, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025

Jul 21, 2025, 9:00 AM EDT - 5 months ago

IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards

Jul 10, 2025, 3:10 PM EDT - 6 months ago

IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection

Jun 30, 2025, 9:00 AM EDT - 6 months ago

IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights - A Year of Transformative Progress in Alzheimer's Innovation

Jun 27, 2025, 8:30 AM EDT - 6 months ago

IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025

Jun 23, 2025, 8:30 AM EDT - 6 months ago

IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon

May 22, 2025, 9:30 AM EDT - 7 months ago

IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market

May 12, 2025, 9:30 AM EDT - 8 months ago

IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting

Apr 24, 2025, 9:30 AM EDT - 8 months ago

IGC Pharma Welcomes Strategic Investment from Advisors

Apr 21, 2025, 9:30 AM EDT - 8 months ago

IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs

Apr 8, 2025, 9:30 AM EDT - 9 months ago

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

Apr 1, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

Mar 26, 2025, 9:00 AM EDT - 9 months ago

IGC Pharma's Phase 2 Clinical Trial Interim Data Demonstrates Significant Reduction in Sleep Disturbances

Mar 20, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

Mar 17, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in Florida

Mar 12, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q3 results. We believe more positive clinical data in 2025 to be strong catalysts for stock.

Mar 10, 2025, 9:00 AM EDT - 10 months ago

IGC Pharma Announces Equity Analyst Update by Alliance Global Partners (AGP) about the "Progressing Alzheimer-targeting efforts with notable Phase 2 CALMA interim results"

Mar 4, 2025, 9:00 AM EST - 10 months ago

IGC Pharma Expands AI Platform With Advanced Diagnostic Model for Alzheimer's and Dementia Detection

Feb 20, 2025, 9:00 AM EST - 11 months ago

IGC Pharma Expands Holiby(TM) Product Line With 'Longevity' and 'Renew' - Targeting the Multi-Billion-Dollar Anti-Aging Market

Feb 18, 2025, 8:30 AM EST - 11 months ago

IGC Pharma Reports Third Quarter Fiscal 2025 Results

Feb 11, 2025, 8:30 AM EST - 11 months ago

IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of Holiby(TM)

Jan 28, 2025, 8:30 AM EST - 11 months ago

IGC Pharma Named Top 15 Finalist in NIA PREPARE Challenge for AI-Driven Early Detection of Alzheimer's Disease

Jan 13, 2025, 8:30 AM EST - 1 year ago

IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets

Jan 8, 2025, 8:30 AM EST - 1 year ago

IGC Pharma Names IGC-AD1 Phase 2 Clinical Trial for Alzheimer's Agitation "CALMA" and Expands Recruitment Strategy

Dec 19, 2024, 7:00 PM EST - 1 year ago

IGC Pharma Announces Participation in BioPartnering at JPM Alongside the J.P. Morgan 43rd Annual Healthcare Conference 2025

CarlSpagler Dec. 26 at 9:05 PM

$IGC where do these analyst price targets come from? lol

1 · Reply

Amraa2 Dec. 26 at 8:08 PM

$IGC why so fking hard to get to .5

0 · Reply

theflynews Dec. 26 at 6:48 PM

Trump Weekly: President strikes deal with drugmakers, delays some tariffs - $IGC - https://thefly.com/permalinks/entry.php/IGCid4262021?176

0 · Reply

UCIdidmyDD Dec. 25 at 5:26 PM

2 · Reply

dwiz5 Dec. 24 at 1:34 AM

$IGC 35,183 shares great dip buying G/L

0 · Reply

Ottway Dec. 23 at 3:04 PM

$IGC dilution king $CGC $TLRY these companies dont make money they scam us by rs and dilution… insanity how retail got dumped on

1 · Reply

Ottway Dec. 22 at 11:45 PM

$CGC dilution killed the rally baby $IGC amazing how these companies operate amazing this is legal…

0 · Reply

Jimbob3016 Dec. 22 at 12:27 PM

TLX Phase 3 approval $FLGC #1 on Stocktwits $IGC squeeze

0 · Reply

PineappleInvesting Dec. 22 at 7:09 AM

0 · Reply

Clkrrb Dec. 19 at 6:55 PM

$IGC IGC’s Santa Claus rally is giving us a lump of coal.

0 · Reply

IGC Dec. 19 at 5:14 PM

$IGC President Trump’s move to reclassify cannabis marks the most significant federal cannabis policy shift in decades. As the regulatory landscape evolves, continues its focus on advancing clinically validated cannabinoid medicines within the pharmaceutical framework. #AlzheimersResearch #CannabinoidMedicine #IGCPharma

0 · Reply

Ottway Dec. 19 at 4:17 PM

$IGC you know its dilution when you get news like this and she drops lol $TLRY $CGC i made the mistake now im a bagholder sad day

0 · Reply

Ottway Dec. 19 at 3:58 PM

$IGC extreme dilution going on here

0 · Reply

Ottway Dec. 19 at 3:31 PM

$IGC incredible trash i was right

0 · Reply

DiddyK0ng Dec. 19 at 3:29 PM

$IGC crap stock

0 · Reply

JohnTrack Dec. 19 at 3:17 PM

$IGC watching opening prints!

0 · Reply

Golferhack12 Dec. 19 at 3:14 PM

$IGC waiting all these years for this to happen and now the socks at all time low

1 · Reply

The_Izer Dec. 19 at 2:59 PM

$IGC bought more this morning, let get this thing going

0 · Reply

distanceswimmer Dec. 19 at 2:16 PM

$IGC volume precedes price

0 · Reply

WarriorSTC Dec. 19 at 2:11 PM

$IGC

0 · Reply

JohnTrack Dec. 19 at 2:08 PM

$IGC Patents on deck!!! https://www.rapidticker.com/news/igc-igc-pharma-secures-new-us-16d2b8

0 · Reply

WarriorSTC Dec. 19 at 2:06 PM

$IGC US patent granted on Cannabis related medicinal products https://www.stocktitan.net/news/IGC/igc-pharma-secures-new-u-s-patent-as-pharmaceutical-cannabinoids-2k6e0mhs2cym.html

0 · Reply

Market Cap	27.85M
Revenue (ttm)	1.27M
Net Income (ttm)	-7.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-560.63%
Debt to Equity Ratio	0.02

Volume	339,600
Avg Vol	839,086
Day's Range	N/A - N/A
Shares Out	92.87M
Stochastic %K	14%
Beta	0.24
Analysts	Sell
Price Target	$3.88